Scientific evidence on longevity of Covid antibodies still evolving: Govt

Studies to understand the duration of persistence of SARS-CoV-2 antibodies have been undertaken in India and abroad by multiple independent investigators and vaccine manufacturers

Coronavirus
Photo: Shutterstock
Press Trust of India New Delhi
2 min read Last Updated : Dec 07 2021 | 5:56 PM IST

Studies to understand the duration of persistence of SARS-CoV-2 antibodies have been undertaken in India and abroad by multiple independent investigators and vaccine manufacturers and scientific evidence on it is still evolving, the Rajya Sabha was informed on Tuesday.

In written reply to a question in the Upper House of Parliament, Minister of State for Health Bharati Pravin Pawar said that in addition to antibodies, other immune mechanisms like cellular or T cell based immune response and memory B cells are created because of vaccination and are responsible for protection against infection.

She was responding to the question on whether the government has conducted any studies to check if there is a case of declining vaccine immunity amongst the elderly population.

Asked whether the government is considering giving booster shots to improve immunity, Pawar said, "The National Technical Advisory Group on Immunization (NTAGI) and the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) are deliberating and considering scientific evidences related to dose schedule of COVID-19 vaccines and the need for booster dose."

Adequate doses to vaccinate all eligible first dose and due second dose beneficiaries aged 18 years and above by December 2021 have been made available to states and union territories, she said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccine

First Published: Dec 07 2021 | 5:56 PM IST

Next Story